Sep 05, 2018

Small Caps publication covers DEP® irinotecan candidate’s positive performance in pancreatic cancer model

Small Caps publication covers DEP® irinotecan candidate’s positive performance in pancreatic cancer model

Small Caps, a specialist investment publication, covered the positive news that Starpharma’s DEP® irinotecan showed complete tumour regression and 100% survival in a human pancreatic cancer model.

Read the full article here.

 This contains certain forward-looking statements.